Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
CNBC's Bertha Coombs reports on the latest news from the FTC. South Korea's impeached President Yoon Suk Yeol arrested, local ...
Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
CVS Caremark, OptumRx and St. Louis-based Express Scripts — are part of huge health conglomerates that also own insurers, ...
The Massachusetts Democrat is working with a Missouri Republican, and House members from each party, to press the FTC to ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
President Donald Trump's effect on bank capital rules, crypto policy, antitrust scrutiny, and drug pricing are among key 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback